Huayu Pill ( 化瘀丸) Promotes Fluorescent Doxorubicin Delivery to Tumors in Mouse Model of Lung Cancer
AbstractObjective: To study the effect and mechanism of Huayu Wan ( 化瘀丸, HYW) in combination of chemotherapy of tumor treatment.Methods: HYW serum was added in Lewis cells to assess its impact on fluorescent doxorubicin delivery in vitro. Then, Lewis tumor cells was implanted in C57BL/6 mice via xenograft transplantation. Tumor growth was measured and signal intensity corresponding to blood flow was assessed by laser doppler perfusion imaging (LDPI). Finally, the effect of HYW on the effificacy of doxorubicin was studied.Results: HYW can improve the transfer of fluorescent doxorubicin into cells. The blood flow signal in the tumor tissues of the HYW group was higher than that of the control group (P
Publication date: Available online 25 May 2020Source: Pharmacological ResearchAuthor(s): Ya-Jia Xie, Wei-Na Gao, Qi-Biao Wu, Xiao-Jun Yao, Ze-Bo Jiang, Yu-Wei Wang, Wen-Jun Wang, Wei Li, Shahid Hussain, Liang Liu, Elaine Lai-Han Leung, Xing-Xing Fan
Abstract Non-small lung cancer (NSCLC) is the most common cancer in the world. The epidermal growth factor receptor (EGFR) gene is mutated in approximately 10% of lung cancer cases in the US and 50% of lung cancer in Asia. The representative target therapeutic agent, erlotinib (EGFR tyrosine kinase inhibitor; EGFR TKI), is effective in inactivating EGFR in lung cancer patients. However, approximately 50-60% of patients are resistant to EGFR TKI. These populations are associated with the EGFR mutation. To overcome resistance to EGFR TKI, we discovered a JAK1 inhibitor, CJ14939. We investigated the efficacy of CJ149...
Two newly identified germline genetic variants are associated with an increased risk of lung cancer, researchers report.Reuters Health Information
AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies BOULDER, Colo., May 26, 2020 -- (Healthcare Sales &Marketing Network) -- ArcherDX, Inc., today ... Biopharmaceuticals, Diagnostics, Oncology ArcherDX, AstraZeneca, Anchored Multiplex PCR, Personalized Cancer Monitoring
In this study we used unbiased approach in the lung cancer and colon cell lines (A549 and HTC 116 respectively) to identify universal early transcriptomic signatures of C-1305 cytotoxicity, and to highlight novel pathways responsible for its biological activity. The data obtained with real time analysis was used to select appropriate doses for subsequent RNAseq and biochemical analysis. Furthermore, the RNA samples prior RNA-seq analysis were pre-verified for transcriptomic activation of apoptosis related pathways via qPCR . Since our real time analysis of cell growth have shown that 24 h exposure to C-1305 (at IC50 concen...
Publication date: Available online 23 May 2020Source: Life SciencesAuthor(s): Kai Chen, Zhongjun Shang, Ai-lin Dai, Pei-ling Dai
Publication date: July 2020Source: Process Biochemistry, Volume 94Author(s): Krishnamoorthy Varunkumar, Chidambaram Anusha, Thavamani Saranya, Vaikundamoorthy Ramalingam, Sakthivel Raja, Vilwanathan Ravikumar
Publication date: Available online 24 May 2020Source: Chemico-Biological InteractionsAuthor(s): Virginia Marcia Concato, Fernanda Tomiotto-Pellissier, Taylon Felipe Silva, Manoela Daiele Gonçalves, Bruna Taciane da Silva Bortoleti, Mariana Barbosa Detoni, Elaine da Silva Siqueira, Ana Carolina Jacob Rodrigues, Jéseka Gabriela Schirmann, Aneli de Melo Barbosa-Dekker, Idessania Nazareth Costa, Ivete Conchon-Costa, Milena Menegazzo Miranda-Sapla, Mario Sergio Mantovani, Wander Rogério Pavanelli
Dalton Trans., 2020, Accepted Manuscript DOI: 10.1039/D0DT01535K, PaperCeyda Icsel, Veysel T. Yilmaz, Seyma Aydinlik, Muhittin Ayg ün New Zn(II), Cd(II) and Hg(II) complexes of saccharinate (sac) and 2,6-bis(2-benzimidazolyl)pyridine (bzimpy), [Zn(bzimpy)2](sac)2 •2H2O (Zn), [Cd(sac)2(bzimpy)] (Cd) and [Hg(sac)2(bzimpy)] (Hg), were prepared and fully characterized by spectroscopic methods and X-ray crystallography.... The content of this RSS Feed (c) The Royal Society of Chemistry
Cell Death &Disease, Published online: 26 May 2020; doi:10.1038/s41419-020-2592-zKinesin light chain 4 as a new target for lung cancer chemoresistance via targeted inhibition of checkpoint kinases in the DNA repair network